Nephron Research downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Exact Sciences downgraded to Equal Weight from Overweight at Barclays
- Exact Sciences downgraded to Market Perform from Outperform at William Blair
- Exact Sciences downgraded to Equal Weight from Overweight at Wells Fargo
- Exact Sciences downgraded to Peer Perform from Outperform at Wolfe Research